SELECT PUBLICATIONS

Bendandi M. The role of idiotype vaccines in the treatment of human B-cell malignancies. Expert Rev Vaccines 2004;3(2):163-70. Abstract

Fisher RI et al. New treatment options have changed the natural history of follicular lymphoma. Proc ASH 2004;Abstract 583.

Horning SJ et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23(4):712-9. Abstract

Hurvitz SA, Timmerman JM. Current status of therapeutic vaccines for non-Hodgkin’s lymphoma. Curr Opin Oncol 2005;17(5):432-40. Abstract

Kaminski MS et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9. Abstract

Leitch HA, Connors JM. Vaccine therapy for non-Hodgkin’s lymphoma and other B-cell malignancies. Curr Opin Investig Drugs 2005;6(6):597-604. Abstract

Lewington V. Development of 131I-tositumomab. Semin Oncol 2005;32(1 Suppl 1):50-6. Abstract

Maloney DG. Immunotherapy for non-Hodgkin’s lymphoma: Monoclonal antibodies and vaccines. J Clin Oncol 2005;23(26):6421-8. Abstract

Press OW et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/ iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102(5):1606-12. Abstract